NICE first rejected Kadcyla back in 2014, saying its cost of around £91,000 per patient at full price was too high, and that a small discount was not enough for it to be considered cost effective.

Kadcyla is approved in 113 countries and is the standard of care for people with HER2-positive eBC with residual invasive disease following neoadjuvant treatment, based on previous positive ...

Kadcyla is currently approved by the FDA for the treatment of patients with HER2-positive, metastatic breast cancer previously treated with a taxane and Herceptin. The approval was based on the phase ...

Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment – At ...

KATHERINE researchers found that among patients with HER2-positive early breast cancer, at a median follow-up of 8.4 years Kadcyla showed sustained improvement in invasive disease-free survival over ...

Basel, 06 May 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Kadcyla® (trastuzumab emtansine) for adjuvant (after surgery ...

FDA approved Roche%27s Kadcyla Drug is double-shot of medication New treatment OK%27d for patients with certain form of cancer WASHINGTON (AP) — The U.S. Food and Drug Administration has ...

Kadcyla, a HER2-targeted antibody and microtubule inhibitor conjugate, is also currently approved to treat patients with HER2-positive, metastatic breast cancer who previously received trastuzumab ...

Kadcyla was one of the most expensive drugs on the CDF, costing up to £65,000 per patients, and charity Breast Cancer Now took the unusual step of calling on Roche to lower its price.

BOSTON (CBS) - The FDA approval of the breast cancer drug Kadcyla is getting a welcome reception from a local oncologist. WBZ's Diane Stern spoke with Dr. Eric Winer, ...

Genentech, a member of the Roche Group, announced today positive long-term follow-up data from the pivotal, Phase III KATHERINE study in people with HER2-positive early-stage breast cancer who ...

At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0% treated with Herceptin, an ...